Inbrija 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0017/G 
This was an application for a group of variations. 
28/04/2023 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
12/01/2023 
n/a 
PRAC Recommendation - maintenance 
0/202206 
levodopa 
IAIN/0015 
B.II.b.1.a - Replacement or addition of a 
25/11/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
07/07/2022 
n/a 
PRAC Recommendation - maintenance 
0/202112 
levodopa 
IA/0013/G 
This was an application for a group of variations. 
19/04/2022 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
0/202106 
levodopa 
N/0011 
Minor change in labelling or package leaflet not 
20/12/2021 
connected with the SPC (Art. 61.3 Notification) 
N/0009 
Minor change in labelling or package leaflet not 
05/11/2021 
PL 
PL 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
PRAC Recommendation - maintenance 
0/202012 
levodopa 
IAIN/0007/G 
This was an application for a group of variations. 
05/07/2021 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
28/01/2021 
26/03/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
0/202006 
levodopa 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/107800/202006. 
IB/0005 
B.IV.1.a.1 - Change of a measuring or administration 
18/11/2020 
n/a 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0003 
B.II.b.3.a - Change in the manufacturing process of 
15/10/2020 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0004/G 
This was an application for a group of variations. 
28/09/2020 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
PSUSA/10780
Periodic Safety Update EU Single assessment - 
23/07/2020 
24/09/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
0/201912 
levodopa 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/107800/201912. 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
